

## BALANCE SHEETS

	March 31, 2024	March 31, 2023
	U.S. Dollars	
	Unaudited	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents		1,797,977
Short-term bank deposits		
Marketable Securities		
Trade accounts receivable	8,850,203	3,847,374
Other receivables and prepaid expenses:		
Prepaid expenses	1,469,871	427,052
Government authorities		
Advances to suppliers		
Derivative instruments		
Intercompany balances	(20,538,306)	(16,368,346)
Other		
TOTAL Other receivables and prepaid expenses	(19,068,435)	(15,941,294)
Inventories	15,897,137	26,000,368
TOTAL CURRENT ASSETS	5,678,905	15,704,424
Long Term Receivables and Other Assets	2,695,002	
Long Term Marketable Securities	2,695,002	-
ROU Assets, net	1,281,817	2,014,284
FIXED ASSETS:		
Cost	10,942,395	10,825,457
Less - accumulated depreciation	(6,584,015)	(5,436,818)
	4,358,380	5,388,639
INTANGIBLE ASSETS AND DEFERRED COSTS, NET		
DEFERRED INCOME TAXES	4,045,009	5,207,289
TOTAL ASSETS	\$ 18,059,113	\$ 28,314,636

## BALANCE SHEETS

	March 31, 2024	March 31, 2023
	U.S. Dollars	
	Unaudited	
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Short-term bank credit	\$ (1,442,288)	
Current maturities of long-term debt		
Accounts payable:		
Trade payables	(3,827,381)	(6,073,348)
Other current liabilities:		
Returns reserve	(104,178)	(821,525)
Payable to Government Authorities		
Due to customers		
Lease Liability	(945,814)	(715,586)
Employees and payroll accruals	(2,207,194)	(4,039,674)
Deferred revenue		
Accrued income taxes	342,375	(4,492,594)
Legal and audit fees		
Settlements and loss contingencies		
Accrued expenses	(4,645,637)	(5,347,752)
Derivative instruments		
Suppliers of property, plant and equipment		
Payable on Purchase of treasury stock		
Payable on Purchase of Marketable Securities		
Other		
TOTAL Other current liabilities	<u>(7,560,449)</u>	<u>(15,417,130)</u>
TOTAL CURRENT LIABILITIES	<u>(12,830,118)</u>	<u>(21,490,478)</u>
LONG-TERM LIABILITIES:		
Long-term debt, net of current maturities		
Deferred income taxes		
Derivative instruments		
Other long-term liabilities	(1,099,088)	(2,914,130)
	<u>(1,099,088)</u>	<u>(2,914,130)</u>
SHAREHOLDERS' EQUITY	<u>(4,129,907)</u>	<u>(3,910,028)</u>
	<u>\$ (18,059,113)</u>	<u>\$ (28,314,636)</u>

Date of approval of the  
financial statements

William Coote  
VP, Chief Financial Officer

## STATEMENTS OF INCOME

	For the Year Ended March 31, 2024	For the Year Ended March 31, 2023
	U.S. Dollars	
	Unaudited	
Sales	\$ 74,923,038	\$ 73,744,610
Cost of sales	36,607,342	31,002,162
Gross profit	38,315,696	42,742,448
Research and development	-	
Selling and marketing expenses	47,865,617	44,424,494
Settlements and loss contingencies		
General and administrative expenses	21,263,270	25,729,068
Operating income	(30,813,191)	(27,411,115)
Financing income, net	1,337,834	829,897
Other expenses	31,567,179	25,839,192
Income before taxes on income	(583,845)	(2,401,820)
Taxes on income	(1,923,725)	(344,130)
Discontinued operation		
Net income for the period before subsidiaries and dividend	1,339,879	(2,057,690)
Dividend income, net		
Subsidiaries		
Net income for the period	\$ 1,339,879	\$ (2,057,690)

Alchemee LLC

---

Changes in Shareholders' Equity

---

	Share Capital	Additional paid in capital	Accumulated other comprehensive loss	Treasury stock	Dividend	Retained Earnings	Total Shareholders' Equity
	<b>U.S. Dollars</b>						
	<b>Un-audited</b>						
<b>Balance at March 31, 2023</b>	-	(21,671,643)	(246,724)	-	-	19,128,339	(2,790,028)
Foreign Currency translation adjustments							-
Unrealized losses on available for sale marketable securities							-
Treasury stock							-
Net income						(1,339,879)	(1,339,879)
<b>Balance at March 31, 2024</b>	-	(21,671,643)	(246,724)	-	-	17,788,460	(4,129,907)